KINDAI UNIVERSITY


*A space between the first name and last name, please enter

Hirotsugu Uemura

Profile

FacultyDepartment of Medicine
PositionSenior Administrator
Degree
Commentator Guidehttp://www.kindai.ac.jp/meikan/748-uemura-hirotsugu.html
URL
Mail
Last Updated :2018/12/01

Research Activities

Published Papers

  • Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial., 1. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI., Lancet Oncol., 19(4), 451 - 460, Apr. 2018 , Refereed
  • Prostate cancer immunotherapy: where are we and where are we going?, De Velasco MA, Uemura H., Curr Opin Urol., 28(1), 15 - 24, Jan. 2018 , Refereed
  • Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury, Shimizu N, Doyal MF, Goins WF, Kadekawa K, Wada N, Kanai AJ, de Groat WC, Hirayama A, Uemura H, Glorioso JC, Yoshimura N., Neuroscience, 364, 190 - 201, Nov. 2017 , Refereed
  • Personalized peptide vaccines and their relation to other therapies in urological cancer., Kimura T, Egawa S, Uemura H, Nature reviews. Urology, 14(8), 501 - 510, Aug. 2017 , Refereed
  • Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer., Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H, International journal of clinical oncology, Aug. 2017 , Refereed
  • Increased Urine Production Due to Leg Fluid Displacement Reduces Hours of Undisturbed Sleep., Kiba K, Hirayama A, Yoshikawa M, Yamamoto Y, Torimoto K, Shimizu N, Tanaka N, Fujimoto K, Uemura H, Lower urinary tract symptoms, Jul. 2017 , Refereed
  • Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study., Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S, Japanese journal of clinical oncology, 47(7), 639 - 646, Jul. 2017 , Refereed
  • Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study., Oya M, Tomita Y, Fukasawa S, Shinohara N, Habuchi T, Rini BI, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Uemura H, Cancer science, 108(6), 1231 - 1239, Jun. 2017 , Refereed
  • Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases., Uemura H, Uemura H, Matsubara N, Kinuya S, Hosono M, Yajima Y, Doi T, International journal of clinical oncology, May 2017 , Refereed
  • Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma., Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H, International immunopharmacology, 44, 197 - 202, Mar. 2017 , Refereed
  • Acotiamide hydrochloride hydrate added to combination treatment with an α-blocker and a cholinergic drug improved the QOL of women with acute urinary retention: case series., Sugimoto K, Akiyama T, Shimizu N, Matsumura N, Hashimoto M, Minami T, Nose K, Nozawa M, Yoshimura K, Uemura H, Research and reports in urology, 9, 141 - 143, 2017 , Refereed
  • Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma., Nozawa M, Sugimoto K, Ohzeki T, Minami T, Shimizu N, Adomi S, Saito Y, Nose K, Yoshimura K, Uemura H, International journal of clinical oncology, 21(4), 748 - 755, Aug. 2016 , Refereed
  • Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study., Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, Naito S, Akaza H, Japanese journal of clinical oncology, Aug. 2016 , Refereed
  • A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer., Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H, European urology, 70(1), 35 - 41, Jul. 2016 , Refereed
  • Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury., Tsuji H, Wang W, Sunil J, Shimizu N, Yoshimura K, Uemura H, Peck AB, Khan SR, World journal of urology, 34(1), 89 - 95, Jan. 2016 , Refereed
  • An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy., Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K, Clinical cancer research : an official journal of the American Association for Cancer Research, 22(1), 54 - 60, Jan. 2016 , Refereed
  • Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. , De Velasco MA, Kura , Yoshikawa , Nishio , Davies BR, Uemura H., Oncotarget. , 7(13), 15959 - 15976, 2016 , Refereed
  • Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy., Yamamoto Y, Kiba K, Yoshikawa M, Hirayama A, Kunikata S, Uemura H, Research and reports in urology, 8, 225 - 231, 2016 , Refereed
  • Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis., Nozawa M, Hara I, Matsuyama H, Iki M, Nagao K, Nishioka T, Komura T, Esa A, Uejima S, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uemura H, World journal of urology, 33(9), 1263 - 1268, Sep. 2015 , Refereed
  • Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma., Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H, Journal of immunotherapy (Hagerstown, Md. : 1997), 38(7), 285 - 291, Sep. 2015 , Refereed
  • Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma., Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H, International journal of clinical oncology, 20(4), 790 - 795, Aug. 2015 , Refereed
  • Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study., Yokoyama O, Tsujimura A, Akino H, Segawa N, Tamada S, Oguchi N, Kitagawa Y, Tsuji H, Watanabe A, Inamoto T, Shimizu N, Fujiuchi Y, Katsuoka Y, Azuma H, Matsuda T, Namiki M, Uemura H, Okuyama A, Nonomura N, Fuse H, Nakatani T, World journal of urology, 33(5), 659 - 667, May 2015 , Refereed
  • New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles., Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco MA, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H, International immunopharmacology, 26(1), 133 - 138, May 2015 , Refereed
  • Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer., Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, Yoshikawa K, Nishio K, Uemura H, Journal of translational medicine, 13, 150, May 2015 , Refereed
  • Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. , Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, Kamba T, Kato M, Nakai Y, Furuse H, Kume H, Ide H, Kitamura H, Yokomizo A, Kimura T, Tomita Y, Ohno K, Kakehi Y., Int J Clin Oncol. , 20(5), 1026 - 1034, 2015 , Refereed
  • Conditional PTEN-deficient mice as a prostate cancer chemoprevention model., Koike H, Nozawa M, De Velasco MA, Kura Y, Ando N, Fukushima E, Yamamoto Y, Hatanaka Y, Yoshikawa K, Nishio K, Uemura H, Asian Pacific journal of cancer prevention : APJCP, 16(5), 1827 - 1831, 2015 , Refereed
  • Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study., Shimizu N, Minami T, Sugimoto K, Saito Y, Yamamoto Y, Hayashi T, Tsuji H, Nozawa M, Yoshimura K, Ishii T, Uemura H, Nakamatsu K, World journal of urology, 32(6), 1423 - 1432, Dec. 2014 , Refereed
  • Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma., Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H, Japan Axitinib Phase II Study Group., Cancer science, 105(12), 1576 - 1583, Dec. 2014 , Refereed
  • A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study)., Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H, Japanese journal of clinical oncology, 44(12), 1216 - 1226, Dec. 2014 , Refereed
  • Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum., Yamamoto Y, Nozawa M, Shimizu N, Minami T, Yoshimura K, Uemura H, International journal of urology : official journal of the Japanese Urological Association, 21(11), 1183 - 1184, Nov. 2014 , Refereed
  • Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer., Matsuyama H, Shimabukuro T, Hara I, Kohjimoto Y, Suzuki K, Koike H, Uemura H, Hayashi T, Ueno M, Kodaira K, Tomita Y, Sakurai T, Shimizu N, International journal of clinical oncology, 19(5), 946 - 954, Oct. 2014 , Refereed
  • Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma., Ohzeki T, Fukasawa S, Komaru A, Namekawa T, Sato Y, Takagi K, Kobayashi M, Uemura H, Ichikawa T, Ueda T, International journal of urology : official journal of the Japanese Urological Association, 21(10), 1065 - 1068, Oct. 2014 , Refereed
  • Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer., De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H, Carcinogenesis, 35(9), 2142 - 2153, Sep. 2014 , Refereed
  • Cutaneous angiosarcoma at an interval of thirty-six years from radiation for a testicular germ cell tumor., Kato M, Oiso N, Nishimoto M, Mori Y, Katoh Y, Uemura H, Kawada A, European journal of dermatology : EJD, 24(5), 622 - 623, Sep. 2014 , Refereed
  • Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system., Harashima N, Minami T, Uemura H, Harada M, Molecular cancer, 13, 217, Sep. 2014 , Refereed
  • Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis., Nozawa M, Inagaki T, Nagao K, Nishioka T, Komura T, Esa A, Kitagawa M, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uejima S, Matsuyama H, Hara I, Uemura H, International journal of clinical oncology, 19(4), 693 - 701, Aug. 2014 , Refereed
  • Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia., Ye D, Eto M, Chung JS, Kimura G, Chang WC, Chang YH, Pang ST, Lee JL, Niu Y, Gurney H, Uemura H, Clinical genitourinary cancer, 12(4), 225 - 233, Aug. 2014 , Refereed
  • Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition., Tsuji H, Shimizu N, Nozawa M, Umekawa T, Yoshimura K, De Velasco MA, Uemura H, Khan SR, Urolithiasis, 42(3), 195 - 202, Jun. 2014 , Refereed
  • Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma., Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H, International immunopharmacology, 20(1), 59 - 65, May 2014 , Refereed
  • Examination of the effect of changing to azilsartan from candesartan in renal transplant patients., Ishii T, Yasuda M, Saito Y, Mori Y, Hayashi T, Uemura H, Nose K, Nishioka T., Transplant Proc. , 46(2), 492 - 495, 2014 , Refereed
  • Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group., Inamoto T, Azuma H, Nonomura N, Nakatani T, Matsuda T, Nozawa M, Ueda T, Kinoshita H, Nishimura K, Kanayama HO, Miki T, Tomita Y, Yoshioka T, Tsujihata M, Uemura H, Asian Pacific journal of cancer prevention : APJCP, 15(4), 1811 - 1815, 2014 , Refereed
  • Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl-induced cystitis., Shimizu N, De Velasco MA, Umekawa T, Uemura H, Yoshikawa K, International journal of urology : official journal of the Japanese Urological Association, 20(11), 1136 - 1143, Nov. 2013 , Refereed
  • Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice., Nozawa M, Nonomura N, Ueda T, Nishimura K, Kanayama HO, Miki T, Nakatani T, Tomita Y, Azuma H, Yoshioka T, Tsujihata M, Uemura H, Japanese journal of clinical oncology, 43(11), 1132 - 1138, Nov. 2013 , Refereed
  • Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy., Yoshimura K, Uemura H, International journal of urology : official journal of the Japanese Urological Association, 20(8), 744 - 755, Aug. 2013 , Refereed
  • Pazopanib versus sunitinib in metastatic renal-cell carcinoma., Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK, The New England journal of medicine, 369(8), 722 - 731, Aug. 2013 , Refereed
  • Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial., Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H, Japanese journal of clinical oncology, 43(6), 616 - 628, Jun. 2013 , Refereed
  • Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy., Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T, BJU international, 111(6), 928 - 933, May 2013 , Refereed
  • STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma., Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S, Japan Immunotherapy SNPs-Study Group for Kidney Cancer., European urology, 63(4), 745 - 752, Apr. 2013 , Refereed
  • Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts., Shimazui T, Yoshikawa K, Miyazaki J, Kojima T, Inai H, Ando S, Uemura H, Uchida K, Nishiyama H, International journal of oncology, 42(2), 543 - 548, Feb. 2013 , Refereed
  • Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma., Yoshimura K, Minami T, Nozawa M, Uemura H., Br J Cancer., 108(6), 1260 - 1266, 2013 , Refereed
  • Survey on lower urinary tract symptoms and sleep disorders in patients treated at urology departments., Shimizu N, Nagai Y, Yamamoto Y, Minami T, Hayashi T, Tsuji H, Nozawa M, Yoshimura K, Ishii T, Uemura H, Oki T, Sugimoto K, Nose K, Nishioka T, Nature and science of sleep, 5, 7 - 13, 2013 , Refereed
  • Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery., Sugimoto K, Shimizu N, Oki T, Nose K, Nishioka T, Adomi S, Ohzeki T, Esa A, Uemura H, Cancer management and research, 5, 85 - 89, 2013 , Refereed
  • Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery., Sugimoto K, Shimizu N, Nose K, Tahara H, Imanishi M, Nishioka T, Esa A, Kajikawa H, Uemura H, Journal of Cancer, 4(6), 514 - 518, 2013 , Refereed
  • Procalcitonin as a useful marker to decide upon intervention for urinary tract infection., Sugimoto K, Shimizu N, Matsumura N, Oki T, Nose K, Nishioka T, Uemura H, Infection and drug resistance, 6, 83 - 86, 2013 , Refereed
  • Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms., Shimizu N, Nozawa M, Sugimoto K, Yamamoto Y, Minami T, Hayashi T, Yoshimura K, Ishii T, Uemura H, Research and reports in urology, 5, 113 - 119, 2013 , Refereed
  • Sorafenib rechallenge in patients with metastatic renal cell carcinoma., Nozawa M, Yamamoto Y, Minami T, Shimizu N, Hatanaka Y, Tsuji H, Uemura H, BJU international, 110(6 Pt B), E228 - 34, Sep. 2012 , Refereed
  • Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway., De Velasco MA, Uemura H, Advances in urology, 2012, 419348, 2012 , Refereed
  • Personalized cancer therapy for urological cancers: from bench to bedside and back., Uemura H, Nelson C, Schalken JA, Klotz L, Advances in urology, 2012, 298105, 2012 , Refereed
  • Effect of Partial Bladder Outlet Obstruction on the Morphology of Elastin in Rabbit Bladder Smooth Muscle., Sugimoto K, Matsumoto S, Ito H, Uemura H, Lower urinary tract symptoms, 2(2), 71 - 75, Sep. 2010 , Refereed
  • A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety., Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H, Japanese journal of clinical oncology, 40(3), 194 - 202, Mar. 2010 , Refereed
  • Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer., Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, Komatsu N, Yamada A, Itoh K, Cancer science, 101(3), 601 - 608, Mar. 2010 , Refereed
  • Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients., Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y, European urology, 57(2), 317 - 325, Feb. 2010 , Refereed
  • Effect of Edaravone on Ischemia/Reperfusion Injury in Rat Urinary Bladder-Changes in Smooth Muscle Cell Phenotype and Contractile Function., Matsumoto S, Hanai T, Shimizu N, Sugimoto K, Uemura H., Aktuelle Urol., 41, S46 - S49, 2010 , Refereed
  • Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals., Umekawa T, Tsuji H, Uemura H, Khan SR, BJU international, 104(1), 115 - 120, Jul. 2009 , Refereed
  • Bladder outlet obstruction accelerates bladder carcinogenesis., Matsumoto S, Shimizu N, Hanai T, Uemura H, Levin R, BJU international, 103(10), 1436 - 1439, May 2009 , Refereed
  • Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model., Matsumoto S, Hanai T, Uemura H, Levin RM, BJU international, 103(7), 987 - 990, Apr. 2009 , Refereed
  • GFP image analysis in the mouse orthotopic bladder cancer model., De Velasco MA, Tanaka M, Anai S, Tomioka A, Nishio K, Uemura H, Oncology reports, 20(3), 543 - 547, Sep. 2008 , Refereed
  • Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation., Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y, Molecular cancer therapeutics, 7(7), 1864 - 1870, Jul. 2008 , Refereed
  • STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma., Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(19), 2785 - 2791, Jul. 2007 , Refereed
  • Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles., Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M, Cancer immunology, immunotherapy : CII, 56(5), 689 - 698, May 2007 , Refereed
  • Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells., Umekawa T, Byer K, Uemura H, Khan SR, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 20(5), 870 - 878, May 2005 , Refereed
  • The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma., Shimazui T, Yoshikawa K, Uemura H, Hirao Y, Saga S, Akaza H, Cancer, 101(5), 963 - 968, Sep. 2004 , Refereed
  • Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma., Shimazui T, Yoshikawa K, Uemura H, Kawamoto R, Kawai K, Uchida K, Hirao Y, Saga S, Akaza H, International journal of oncology, 23(4), 1049 - 1054, Oct. 2003 , Refereed
  • Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma., Shimizu K, Uemura H, Yoshikawa M, Yoshida K, Hirao Y, Iwashima K, Saga S, Yoshikawa K, Oncology reports, 10(5), 1307 - 1311, Sep. 2003 , Refereed
  • Non-ischemic nephron-sparing surgery for small renal cell carcinoma: complete tumor enucleation using a microwave tissue coagulator., Hirao Y, Fujimoto K, Yoshii M, Tanaka N, Hayashi Y, Momose H, Samma S, Okajima E, Uemura H, Yoshida K, Ozono S, Japanese journal of clinical oncology, 32(3), 95 - 102, Mar. 2002 , Refereed
  • Aberrations of the p14ARF and p16INK4a genes in renal cell carcinomas., Kawada Y, Nakamura M, Ishii E, Shimada K, Oosterwijk E, Uemura H, Hirao Y, Kim SC, Konishi N. , J. Cancer Res., 92, 1293 - 1299, 2001 , Refereed
  • Aortic calcification index(ACI): A parameter to predict renal function following nephrectomy; A preliminary reports, HiraoY, Yoshii M, Tsujimoto S, Uemura H, Yoshida K, Ozono S, Okajima E., Aktuel Urol, 31, 2 - 3, 2000 , Refereed
  • ctivation of the MN/CA9 is associated with hypomethylation in humanrenal cell carcinomas., Cho M, Grabmaier K, Kitahori Y, Hiasa Y, Nakagawa Y, Uemura H, Hirao Y, Ohnishi T, Yoshikawa K, Ooesterwijk E., Mol.Carcinogenesis, 27, 184 - 189, 2000 , Refereed
  • MN/CA /G250 as a potential target for immunotherapy of renal cell carcinomas., UEMURA Hirotsugu, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E., Brit.J.Cancer , 81, 741 - 746, 1999 , Refereed
  • MN/CA IX/G250 as potential target for immunotherapy of renal cell carcinomas, British Journal of Cancer, 81, 741 - 746, 1999
  • Expression of MN antigen in urologic cancer: potential tool as a therapeutic target, UEMURA Hirotsugu, Nakagawa Y, Hirao Y, Okajima E, Yoshikawa K, Oosterwijk E., Aktuel Urol., 31, 52 - 54, 2000 , Refereed
  • Detection of circulating MN/CA9 positive renal cell carcinoma cells during operation., Aktuel. Urol., 34, 270 - 272, 2003
  • OAB, 7(*), 769 - 775, Jul. 2004
  • Long-term results of transurethral microwave thermotherapy, Jpn J Endurol ESWL, 17, 225 - 228, 2004
  • Analysis of bone mineral density in urolithiasis patients, Internal Journal of Urology, Apr. 2005
  • Edaravone protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder, Urology, 66(4), 892 - 896, Oct. 2005
  • Medial prefrontal cortex lesions inhibit reflex micturition in anethetized rats., Matsumoto S, Hanai T, Yoshioka N, Shimizu N, Sugiyama T, Uemura H, Neuroscience Resarch, 54(1), 66 - 70, Jan. 2006 , Refereed
  • A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma, Clinical Cancer Research, 12(6), 1768 - 1775, Mar. 2006
  • Experience with lapalroscopic splenelectomy for ABO-incompatible living renal transplantation, Transplantation proceedings, (38), 1985 - 1986, Jun. 2006
  • A malignant Leydig cell tumor of the testis, Internarional Urology and Nephrology, 38(2), 291 - 292, Jul. 2006
  • Can Monitoring of Serum 8-OHdG Level for 2 Hours After Renal Transplantation Predict Prognosis of the Graft?, Transplantation Proceedings, 38(7), 2014 - 2015, Sep. 2006
  • Creatol, an oxidative product of creatinine in kidney transplant patients, as a useful determinant of renal function: a preliminary study., Transplantation Proceedings, 38(7), 2009 - 2011, Sep. 2006
  • A Phase I Trial ofVaccination of CA9-Derived Peptides for HLA-A24-Positive Patientswith Cytokine-Refractory Metastatic Renal Cell Carcinoma, Clinican Cancer Research, 12(6), 1768 - 1775, 2006
  • Bladder leiomyosarcome in a boy, International Urology and Nephrology, 38(3-4), 549 - 551, 2006
  • Tumor vaccines in renal cell caricinoma, World J Urol, 26, 147 - 154, 2008
  • Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer, Cancer Science, 101(3), 601 - 608, 2009
  • A phase II study of Sunitinib in Japanese ptients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety, Japanese Journal of Clinical Oncology, 40(3), 194 - 202, 2009
  • Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination, Cancer Biol Ther, 10(12), 1266 - 1279, Dec. 2010
  • efficacy of Carvedilol for ischemia/reperfusion-induced oxidative renal injury in rats, transplantation proceeedings, 40, 2139 - 2141, 2010
  • Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer., BJU Iit, 108, 187 - 195, 2010
  • Kidney Cancer Working Group Report, Jpn.J.Clin.Oncol., Suppl(1), i51 - i56, 2010
  • Molecular genetic events associated with renal cell carcinoma and its implication to treatment by molecular target therapy, Int.J.Urol, 17, 198 - 205, 2010
  • Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma, Am.J.Respire.Crit.Care.Med., 182, 396 - 403, 2010
  • A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard doseEMP in patients with castration resistant prostate cancer, Cancer Immunol Immunother, 59, 1001 - 1009, 2010
  • Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma, Jpn J Clin Oncol, 40, 1166 - 1172, 2010
  • Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1, Jpn J Clin Oncol, 41, 17 - 24, 2010
  • APhase IStudyof Personalized PeptideVaccination Using14Kinds ofVaccine inCombinationWith Low-DoseEstramustineinHLA-A24-PositivePatients WithCastration-Resistant ProstateCancer, The Prostate, 71, 470 - 479, 2010
  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 378, 1931 - 1939, Dec. 2011
  • Basic research in kidney cancer, Eur.Urol., 60, 622 - 633, 2011
  • A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A-24-positive patients with castration-resistant prostate cancer, The Prostate, 71, 470 - 479, 2011
  • Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma, European Journal of Cancer, 47, 2592 - 2602, 2011
  • Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity, The Journal of Urology, 186, 2470 - 2477, 2011
  • Maintenance therapy with bacillus calmette-guerin connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle-invasive bladder cancer, BJU International, 108, 187 - 195, 2011
  • A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system, Oncology Reports, 26, 327 - 333, 2011
  • Genomic aberrations in renal cell carcinomas detected by restriction landmark genomic scanning. , Cho M, Konishi N, Yamamoto K, Inui T, Kitahori Y, Nakagawa Y, Uemura H, Hirao Y, Hiasa Y., Eur.J.Cancer, 34(13), 2112 - 2118, 1998 , Refereed
  • Detection of DNA amplification in human renal cell carcinoma cell lines using restriction landmark genomic scanning., Cho M, Konishi N, Kitahori Y, Hiasa Y, Nakagawa Y, Uemura H, Hirao Y, Oosterwijk E., Cell.mol.Biol., 44, 913 - 918, 1998 , Refereed
  • Radiation hybrid mapping of the human MN/CA9 locus to chromosome band 9p12-p13., Nakagawa Y, Uemura H, Hirao Y, Yoshida K, Saga S, Yoshikawa K., Genomics, 53, 118 - 119, 1998 , Refereed
  • Experimental model of renal tumors in polycystic kidney: effects of long-term 2-amino-4,5-diphenylthiazole administration in rats treated with N-ethyl-N-hydroxyelnitrosamine. , Tsumatani K1, Nakagawa Y, Kitahori Y, Konishi N, Uemura H, Ozono S, Hirao Y, Okajima E, Hirao K, Hiasa Y., Toxicol. Pathol. , 25, 363 - 371, 1997 , Refereed
  • Induction of tumor regression by passive transfer of antibody from mice vaccinated with anti-idiotype antibodies resembling a human renal cell carcinoma-associated antigen, UEMURA Hirotsugu,Okajima E, Deburyne FMJ, Oosterwijk E., Urol. Oncol., 1, 73 - 79, 1995 , Refereed
  • Immunization with anti-idiotype monoclonal antibodies bearing the internal image of the renal cell carcinoma-associated antigen G250 induces specific cellular immune responses., UEMURA Hirotsugu,Okajima E, Deburyne FMJ, Oosterwijk E., Int. J. Cancer, 59, 802 - 807, 1994 , Refereed
  • Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity., UEMURA Hirotsugu,Beniers AJMC, Okajima E, Deburyne FMJ, Oosterwijk E. , Int. J. Cancer, 58, 555 - 561, 1994 , Refereed
  • Clinical aspects of renal cell carcinoma., UEMURA Hirotsugu, Oosterwijk E, Debruyne FMJ., Revista Romana de Urol., 1, 81 - 88, 1994 , Refereed
  • Internal image antiidiotype antibodies related to renal cell carcinoma-associated antigen G250, UEMURA Hirotsugu, Okajima E, Deburyne FMJ, Oosterwjik E. , Int. J. Cancer, 56, 609 - 614, 1994 , Refereed
  • Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal cell carcinoma xenografts., van Dijk J, Uemura H, Beniers AJMC, Peelen WP, Zegveld ST, Fleuren GJ, Warnaar SO, Oosterwjik E., Int. J. Cancer, 56, 262 - 268, 1994 , Refereed
  • Induction of nephrosis by β-cyclodextrin in Beagles., Tabata S, Ozono S, Yamaguchi H, Kitagawa H, Uemura H, Matsuki H, Samma S, Hirao Y, Okajima E, Kitahori Y, Hiasa Y., J Toxicol Pathol, 4, 67 - 73, 1991 , Refereed
  • Tumor markers in rats with renal tumor induced by N-ethyl-N-hydroxuethylnitrosamine., Yamaguchi H, Ozono S, Kitagawa H, Uemura H, Tabata S, Matsuki H, Samma S, Hirao Y, Okajima E, Kitahori Y, Hiasa Y., J Toxicol Pathol, 3, 239 - 244, 1990 , Refereed
  • Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. , Gramaier K, deWeijert M, Uemura H, Shalken J, Oosterwijk E., Urology, 60, 357 - 362, Refereed

Books etc

  • Anti-idiotype antibodies resembling the renal cell carcinoma-associated antiggen development. in Idiotypes in Medicine. Autoimmunity, UEMURA Hirotsugu, Infection and Cancer, Elsevier Science,   1997
    Summary:Uemura H and Oosterwjik E.
  • Tools for vaccination and immunotherapy; (internal image anti-idiotype antibodies resembling the renal cell carcinoma-associated antigen development). in ;Complementary Research on Renal Cell Carcinoma, UEMURA Hirotsugu, Springer-Verlag,   1995
    Summary:Uemura H, Oosterwjik E, Deburyne FMJ.

Conference Activities & Talks

  • New therapies for kidney cancer, 植村 天受, C2 Retreat 2011,   2011 11 , C2 Retreat 2011
  • Use of prostate-specific PTEN conditional knockout mice in prostate cancer prevention and intervention research, 植村 天受, 田中 基幹, 小池 浩之, 山本 豊, 畑中 祐二, 王 一, 清水 信貴, 野澤 昌弘, 吉村 一宏, 西尾 和人, デベラスコ マルコ アントニオ, 愛知医科大学, 第70回日本癌学会総会,   2011 10 , 第70回日本癌学会総会
  • Lumican expression prostate cancer, 植村 天受, デベラスコ マルコ アントニオ, 畑中 祐二, 山本 豊, 田中 基幹, 清水 信貴, 児玉 光正, 荒尾 徳三, 西尾 和人, 医学部泌尿器科学教室, 愛知医科大学, 第70回日本癌学会学術総会,   2011 10 , 第70回日本癌学会学術総会
  • Systemic transduction of p16 INK4A anti-tumor peptide inhibits growth of mbt-2 bladder tumor cell line graft in mice, 植村 天受, Tsukuba, Aichi, Hitachi, Tsukuba, Nasushiobara, Nagoya, AUA Annual Meeting,   2011 05 , AUA Annual Meeting
  • A phase I trial of vegfr1 peptide vaccines for patients with metastatic renal cell carcinoma, 植村 天受, デベラスコ マルコ アントニオ, 吉村 一宏, 野澤 昌弘, 南 高文, AUA Auual Meeting,   2011 05 , AUA Auual Meeting
  • Sorafenib inhibits tumor development and growth in a transgenic mouse model of prostate cancer, 植村 天受, 畑中 祐二, 泉 あやか, 岡崎 絵莉奈, 土井 万貴子, 田中 基幹, 山本 豊, 清水 信貴, 吉村 一宏, 野澤 昌弘, 西尾 和人, デベラスコ マルコ アントニオ, 愛知医科大学, 102nd Auual Meeting AACR,   2011 04 , 102nd Auual Meeting AACR
  • Experience sharing for sequential use of targeted agents and AE management in mRCC, 植村 天受, Asia-Pacific Uro-Oncology Summit 2011,   2011 01 , Asia-Pacific Uro-Oncology Summit 2011
  • Anti-cancer effect of zoledronic acid in prostate cancer, 植村 天受, Asia-Pacific Uro-Oncology Summit 2011,   2011 01 , Asia-Pacific Uro-Oncology Summit 2011
  • Breast and renal cell carcinomas; Improving outcomes by targeting shared signaling pathways., 植村 天受, 浜松オンコロジーセンター, San Camillo Forlanini, 埼玉医科大学, 川崎医科大学, 第48回日本癌治療学会学術集会,   2010 10 , 第48回日本癌治療学会学術集会
  • Systemic transduction of p16INK4A anti-tumor peptide inhibits growth of MBT-2 bladder tumor cell line graft in mice, 植村 天受, 筑波大学医学部泌尿器科学, 愛知医科大学臨床試験センター, 日立総合病院泌尿器科, 筑波大学医学部泌尿器科学, 国際医療福祉大学, 第69回日本癌学会学術総会,   2010 09 , 第69回日本癌学会学術総会
  • The inhibitory effect of renal stone formation by osteopontin siRNA transfection, 辻 秀憲, 清水 信貴, 梅川 徹, 植村 天受, 第98回日本泌尿器科学会総会,   2010 04 , 第98回日本泌尿器科学会総会
    Summary:【目的】オステオポンチン(OPN)は尿路結石形成に対して重要な働きをもつが、その作用はin vitroでは多機能性を有する。今回、結石形成ラット腎にin vivo OPNsiRNA transfectionを行い、結石形成への影響をみた。【方法】target sequenceは、5’AAGGCGCATTACAGCAAACAC3’(5’167―185 3’)。A:コントロール群, B:1.5%エチレングリコール(EG)投与群, C:ラットの尾静脈よりリポフェクションにてOPNsiRNAをtransfectionさせた群, D:腎被膜下にAteloGeneTMを用いてOPNsiRNAを注入した群 を作成。C,D群は1週毎の投与で、3週目に摘出腎のOPN mRNA/OPNタンパク質レベルをリアルタイムPCRにより測定した。尿細管内の結晶沈着と腎組織のカルシウム含有量を原子吸光分析で計測した。【結果・考察】OPNの発現はmRNAで&&蛋白で&&&。尿細管内の結晶沈着はC,D群で有意な減少を認めた。カルシウム含有量はB群:0.143±0.036,C群:0.077±0.003,D群:0.065±0.021でOPNsiRNA transfection群では有意に減少した。OPNはin vivoで全体としては結石形成に促進的に作用
  • Use of nesr infrared fluorescence imaging to determine tumor burden in genetically engineered mice, 植村 天受, デベラスコ マルコ アントニオ, 西尾 和人, 愛知医科大学臨床試験センター, 中外製薬, 近畿大学農学部, 近畿大学農学部, 近畿大学農学部, 101th Annunal Meeting of the American for Cancer Research,   2010 04 , 101th Annunal Meeting of the American for Cancer Research
  • The effects of whole body hyperthermia on tumor growth by a novel far infrared emitter, 植村 天受, デベラスコ マルコ アントニオ, 近畿大学農学部, 近畿大学農学部, 近畿大学農学部, 愛知医科大学臨床試験センター, 101st Annual Meeting of American for Cancer Research,   2010 04 , 101st Annual Meeting of American for Cancer Research
  • Asian experience with the use of novel agents for the treatement of mRCC, 植村 天受, 8th Asia Pacific Oncology Summit,   2010 03 , 8th Asia Pacific Oncology Summit
  • A phase II study of VEGFR1 peptide vaccines for metastatic renal cell carcinoma, 植村 天受, デベラスコ マルコ アントニオ, 野澤 昌弘, 南 高文, 吉村 一宏, 2010 ASCO-GU,   2010 03 , 2010 ASCO-GU
  • A phase I/II study of personalized peptide vaccination therapy for castration resistant prostate cancer, 植村 天受, 南 高文, デベラスコ マルコ アントニオ, 上島 成也, 奈良県立医科大学泌尿器科, 奈良県立医科大学泌尿器科, 久留米大学免疫学, URS 25th Annual Meeting,   2009 08 , URS 25th Annual Meeting
  • A phase II study of carbonic anhydrase 9 peptide vaccines with interferon-alfa in advanced renal cell carcinoma, 植村 天受, 上島 成也, 田中 基幹, 南 高文, 2009 Genitourinary Cancers Symposium,   2009 02 , 2009 Genitourinary Cancers Symposium
  • A phase II study of the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (mRCC), 植村 天受, 北海道大学医学部泌尿器科, 九州大学医学部泌尿器科, 筑波大学医学部泌尿器科, Urological Research Society,   2008 09 , Urological Research Society
  • Using targeted treatments: case discussions, 植村 天受, 5th Asia Pacific Urology Summit,   2008 08 , 5th Asia Pacific Urology Summit
  • Insights into treatment efficacy in Japanese patients with metastatic renal cell carcinoma, 植村 天受, 24th Annual EAU Congress,   2009 03 , 24th Annual EAU Congress
  • Phase I/II study of individualized peptide vaccines for HLA-A2/A24 positive patients with hormonerefractory prostate cancer, 植村 天受, 南 高文, 田中 基幹, 上島 成也, 奈良県立医科大学泌尿器科, 奈良県立医科大学泌尿器科, 久留米大学免疫学, ASCO 2008 Annual Meeting,   2008 05 , ASCO 2008 Annual Meeting
  • Hypertension Promotes BBN-induced Bladder Carcinogenesis in Spontaneously Hypertensive Rat, 松本 成史, 田中 基幹, 上島 成也, 植村 天受, 第66回日本癌学会総会,   2007 10 , 第66回日本癌学会総会
  • Phase I/II study if CA9 peptide vaccination with interferon-alpha in cytokine refractory renal cancer patients, 植村 天受, 田中 基幹, 野澤 昌弘, 松本 成史, 上島 成也, 66th Annual Meeting of the Japanese Cancer Association,   2007 10 , 66th Annual Meeting of the Japanese Cancer Association
  • CA9 peptide vaccination in combination with interferon-alpha in HLA-A24 positive patients with cytokine refractory renal cell carcinoma, 植村 天受, 上島 成也, 清水 信貴, 田中 基幹, 奈良県立医科大学泌尿器科, 奈良県立医科大学泌尿器科, 23rd Annual Meeting Urological Research Society,   2007 10 , 23rd Annual Meeting Urological Research Society
  • The Role of Elastin Fibers in the Bladder and Bladder Functions - Related with Bladder Outlet Obstruction -, 松本 成史, 杉本 公一, 花井 禎, 植村 天受, 伊藤 浩行, 37th Annual Meeting of the International Continence Society (ICS),   2007 08 , 37th Annual Meeting of the International Continence Society (ICS)
  • PDE5 inhibitor (vardenafil) protects rat bladder from partial outlet obstruction-induced contractile dysfunction, 松本 成史, 花井 禎, 清水 信貴, 杉本 公一, 渡邊 絵美, 植村 天受, 37th Annual Meeting of the International Continence Society (ICS),   2007 08 , 37th Annual Meeting of the International Continence Society (ICS)
  • Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease, 松本 成史, 清水 信貴, 花井 禎, 植村 天受, 中野 直樹, 37th Annual Meeting of the International Continence Society (ICS),   2007 08 , 37th Annual Meeting of the International Continence Society (ICS)
  • A Correlative study on the effect of Eviprostat between the clinical parameters and oxidative stress (urinary 8-OHdG) in the treatment of the lower urinary tract symptoms associated with BPH (BPH/LUTS) and on urinary 8-OHdG content in rabbit BOO model, 松本 成史, 花井 禎, 堀川 重樹, 植村 天受, Matsui T Oka M Tanaka M, 37th Annual Meeting of the International Continence Society (ICS),   2007 08 , 37th Annual Meeting of the International Continence Society (ICS)
  • Distribution of elastin fiber in prostate, 杉本 公一, 松本 成史, 花井 禎, 伊藤 浩行, 植村 天受, 102th Annual Meeting of American Urological Association (AUA),   2007 05 , 102th Annual Meeting of American Urological Association (AUA)
  • Bladder protective effects of PDE5 inhibitor -Efficacy of vardenafil on rat bladder with outlet obstruction-, 松本 成史, 渡邊 絵美, 中田 裕佳, 杉本 公一, 清水 信貴, 花井 禎, 植村 天受, 102th Annual Meeting of American Urological Association (AUA),   2007 05 , 102th Annual Meeting of American Urological Association (AUA)
  • A phase I traial of vaccination of personalized peptides for HLA-A2/A24 positive patients with hormone-refractory prostate cancer, 植村 天受, 田中 基幹, 上島成也, 南 高文, 藤本 清秀 平尾 佳彦, 伊東 恭悟, AUA 2007,   2007 05 , AUA 2007
  • Edaravone protects against ischemia / reperfusion-induced morphological and functional changes in rat urinary bladder, 松本 成史, 花井 禎, 吉岡 伸浩, 清水 信貴, 植村 天受, 8th Triennial Meeting of the German-Japanese Confederation of Urology,   2007 03 , 8th Triennial Meeting of the German-Japanese Confederation of Urology
  • CA9 peptide vaccination as a new therapeutic strategy for advanced renal cancer, 植村 天受, 上島成也, 南 高文, 藤本 清秀 平尾 佳彦, The 8th Triennial Meeting of the German-Japanese Confederation of Urology,   2007 03 , The 8th Triennial Meeting of the German-Japanese Confederation of Urology
  • Effect of alpha-blocker before TURP in terms of its dosing period, 吉岡 伸浩, 松本 成史, 清水 信貴, 花井 禎, 植村 天受, 36th Annual Meeting of the International Continence Society (ICS),   2006 11 , 36th Annual Meeting of the International Continence Society (ICS)
  • Edaravone protects against ischemia / reperfusion-induced morphological and functional changes in rat urinary bladder, 松本 成史, 花井 禎, 吉岡 伸浩, 清水 信貴, 植村 天受, 36th Annual Meeting of the International Continence Society (ICS),   2006 11 , 36th Annual Meeting of the International Continence Society (ICS)
  • Distribution of elastin fiber in prostate, 松本 成史, 杉本 公一, 清水 信貴, 花井 禎, 植村 天受, 36th Annual Meeting of the International Continence Society (ICS),   2006 11 , 36th Annual Meeting of the International Continence Society (ICS)
  • Bladder outlet obstruction (BOO) promotes BBN-induced bladder carcinogenesis in rat, 松本 成史, 田中 基幹, 上島 成也, 植村 天受, 第65回日本癌学会総会,   2006 09 , 第65回日本癌学会総会
  • Effect of Edaravone on ischemia/reperfusion injury in rat urinary bladder -Changes in smooth muscle cell phenotype and contractile function-, 松本 成史, 花井 禎, 吉岡 伸浩, 堀川 重樹, 清水 信貴, 植村 天受, The 23rd Japan Korea Urological Congress,   2006 09 , The 23rd Japan Korea Urological Congress
  • A phase I trial of vaccination of tailor-made peptides for HLA-A2/A24 positive patients with hormone-refractory prostate cancer, 植村 天受, Urological Research Society,   2006 09 , Urological Research Society
  • Bladder Outlet Obstruction Promotes BBN - induced Bladder Carcinogenesis in Rat, 松本 成史, 清水 信貴, 土手 健作, 花井 禎, 田中 基幹, 伊藤 浩行, 植村 天受, 8th Asian Congress of Urology,   2006 08 , 8th Asian Congress of Urology
  • Novel gene transduction technology by Credia TF, 田中 基幹, 植村 天受, 外崎 円 梅影 政文 小中 富雄 池田 寿文, The 9th Annual Meeting of the American Society of Gene Therapy,   2006 05 , The 9th Annual Meeting of the American Society of Gene Therapy
  • Phase-1 syudy of carbonic anhydrase 9 peptide vaccines in patients with metastatic renal cell carcinoma, 植村 天受, 田中 基幹, 上島 成也, 平尾 佳彦, 伊東 恭悟, Annual EAU Congress,   2006 04 , Annual EAU Congress
  • Novel gene transduction technology by Credia TF, 田中 基幹, 植村 天受, 外崎 円 梅影 政文 小中 富雄 辻 良平 池田 寿文, The 97th Annual Meeting, American Association for Cancer Research,   2006 03 , The 97th Annual Meeting, American Association for Cancer Research
  • Phase-I/II trial of CA9 peptide vaccines in HLA-A24 positive patients with cytokine refractory renal cell carcinoma, 植村 天受, Urological Research Society,   2005 11 , Urological Research Society
  • Creatol, an Oxidative Product of Creatinine in Kidney Tansplant Patients, as a Useful Determinant of Renal Function; A Preliminary Study, 松本 成史, 花井 禎, 松浦 健, 植村 天受, 西岡 伯, 秋山 ?弘, 9th Congress of the Asian Society of Transplantation,   2005 11 , 9th Congress of the Asian Society of Transplantation
  • Can monitoring of serum 8-OHdG level for two hours after renal transplantation predict prognosis of the graft?, 松本 成史, 花井 禎, 松浦 健, 植村 天受, 西岡 伯, 秋山 ?弘, 9th Congress of the Asian Society of Transplantation,   2005 11 , 9th Congress of the Asian Society of Transplantation
  • Bladder outlet obstruction accelerates carcinogenesis of the bladder, 松本 成史, 植村 天受, Robert M. Levin, 21th Urological Research Society,   2005 11 , 21th Urological Research Society
  • 前立腺癌におけるPTEN癌抑制遺伝子の役割, 田中 基幹, 植村 天受, 冨岡 厚志 高田 聡 穴井 智 平尾 佳彦, 第16回前立腺癌ワークショップ,   2005 09 , 第16回前立腺癌ワークショップ
  • Inductive Coupling Wireless Sensor-Transmitter for Continuous Monitoring of Intra-Bladder Pressure for Unconstrained Urodynamic Study, 松本 成史, 植村 天受, Nakazono K. Takeuchi Y., 5th International Workshop on Biosignal Interpretation (BSI 2005),   2005 09 , 5th International Workshop on Biosignal Interpretation (BSI 2005)
  • 8OHdG before and after TUR, 花井 禎, 松本 成史, 杉山 高秀, 植村 天受, 35th International Continence Society,   2005 08 , 35th International Continence Society
  • Phase-I study of CA9 peptide vaccines in patients with stage IV renal cell carcinoma, 植村 天受, 上島成也, 中西 まこ, 藤本清秀, 平尾佳彦, AUA 2005,   2005 05 , AUA 2005
  • Enhanced efficacy of radiation sensitivity by controlled gene delivery of PTEN expression vector conjugated with cationized gelatin in prostate cancer cells, 田中 基幹, 植村 天受, 高田 聡 冨岡 厚志 松村 善昭 平尾 佳彦, The 100th Annual Meeting, American Urological Association, Inc.,   2005 05 , The 100th Annual Meeting, American Urological Association, Inc.
  • Bladder smooth muscle cell phenotypic changes and detrusor functional changes on ischemia-reperfusion injury in the rat urinary bladder, 松本 成史, 清水 信貴, 杉山 高秀, 植村 天受, 吉岡 伸浩, 花井 禎, Robert M. Levin, 100th American Urological Association,   2005 05 , 100th American Urological Association
  • Enhanced efficacy of radiation sensitivity by controlled gene delivery of PTEN expression vector conjugated with cationized gelatin in prostate cancer cells, 田中 基幹, 植村 天受, 穴井 智 高田 聡 松村 善昭 冨岡 厚志 平尾 佳彦, The 96th Annual Meeting, American Association for Cancer Research,   2005 04 , The 96th Annual Meeting, American Association for Cancer Research
  • Prostate cancer detected from multiple pulmonary metastases: A case report., 杉本 公一, 松本 成史, 田原 秀男, 松浦 健, 植村 天受, 第190回日本泌尿器科学会関西地方会,   2005 02 , 第190回日本泌尿器科学会関西地方会
    Summary:55才、男性。健診にて胸部異常陰影を指摘され精査施行。CTガイド下針生検にてPSA染色陽性腺癌を認め当科紹介。前立腺生検にて確定診断となった。MAB+PE療法にて転移性肺腫瘍は縮小した。
  • Changes in surgery for female stress urinary incontinence over 20 years at this hospital, 清水 信貴, 松本 成史, 吉岡 伸浩, 杉山 高秀, 植村 天受, 4th International congress of the Egyptian society of Uro-gynaecology and Pelvic Floor Studies(ESUG),   2005 02 , 4th International congress of the Egyptian society of Uro-gynaecology and Pelvic Floor Studies(ESUG)
    Summary:Efforts to resolve female stress urinary incontinence spread in the latter half of the 1980s, fueled by the introduction of the Stamey procedure. Afterwards, various techniques to treat stress urinary incontinence were developed and attempted. However, the decline in long-term results with needle bladder neck suspension and anterior colporrhaphy has been criticized in recent years, and the first choice for treatment is shifting to urethral sling surgery with a TVT procedure. Thus, we studied the changes in surgery for female stress urinary incontinence at this hospital. Subjects were diagnosed with stress urinary incontinence by the Urology Department of the Kinki University School of Medicine from 1984-2004 and underwent surgery. Until the early half of the 1990s, Stamey, Raz, and Gittes suspensions and later Vesica and collagen injection were attempted, although TVT was used in all cases starting in the latter half of the 1990s.
  • Drug-induced interstitial pneumonia after post-living renal transplantation, 杉本 公一, 松本 成史, 能勢 和宏, 田原 秀男, 原 靖, 松浦 健, 植村 天受, 第38回日本臨床腎移植学会,   2005 01 , 第38回日本臨床腎移植学会
    Summary:28歳、男性.2002年より慢性腎不全にて腹膜透析導入。2004年5月19日母親(55歳)をドナ−とした生体腎移植術を施行いあた。HLA:A、B;1ミスマッチ、DR;0ミスマッチ、また血液型はドナ−A型、レシピエントAB型の血液型不一致であった。初期免疫抑制はタクロリムス、ミゾリビン、プレドニゾロンおよびバシリキシマブの4剤であった。術後経過は良好であったが、3日目より急に呼吸困難が出現し、間質性肺炎象を認めた。薬剤性間質性肺炎の診断下に免疫抑制剤を変更(Tac→CyA、Mz中止)し、ステロイドパルス療法施行後、肺炎像は軽快し、呼吸困難も改善した。今回われわれは薬剤性間質性肺炎の1例を経験したので若干の文献的考察を加えて報告した。
  • Induction of anti-tumor responses in patients with metastatic renal cell caricinoma by vaccination with peptides-a phase I study, 植村 天受, Fujimoto K., Tanaka M., Yoshikawa M., Nakanishi M., Hirao Y., 27th Congress of the Societe Internatiolale d'Urologie,   2004 10 , 27th Congress of the Societe Internatiolale d'Urologie
  • Controlled gene delivery of PTEN expression vector conjugated with cationized gelatin in prostate cancer cells, 田中 基幹, 植村 天受, 穴井 智 高田 聡 松村 善昭 冨岡 厚志 平尾 佳彦, The 27th Congress of International Society of Urology,   2004 10 , The 27th Congress of International Society of Urology
  • 徐放性PTEN遺伝子薬を用いた、前立腺癌における放射線感受性増強効果, 田中 基幹, 植村 天受, 高田 聡 冨岡 厚志 平尾佳彦, 田畑 泰彦, 第63回日本癌学会総会,   2004 09 , 第63回日本癌学会総会
  • Patients-oriented vaciene tehrapy for hormone refractory prostate cancer, 植村 天受, Fujimoto K., Tanaka M., Tanaka N., Okajima E., Hirao Y., 20th urological Research Society Meeting,   2004 09 , 20th urological Research Society Meeting
  • Tailor-made peptide vaccines for hormone refractory prostate cancer patients, 植村 天受, Fujimoto K., Tanaka M., Tanaka N., Okajima E., Hirao H., 7th Triennial Meeting of the German-Japanese Confederation of Urology,   2004 06 , 7th Triennial Meeting of the German-Japanese Confederation of Urology
  • VHL-dependent and independent regulation of MN/CA9 in renal fell carcinoma cell lines, 植村 天受, Kawada Y., Hirao Y., 第6回VHL国際シンポジウム,   2004 05 , 第6回VHL国際シンポジウム
  • Sensitization of radiotherapy by PTEN gene microcapsule in prostate cancer, 田中 基幹, 植村 天受, 穴井 智 高田 聡 松村 善昭 平尾 佳彦, Charles J Rosser H Barton Grossman, The 95th Annual Meeting, American Association for Cancer Research,   2004 03 , The 95th Annual Meeting, American Association for Cancer Research
  • The development of anti-tumour vaccines derived from MN/CA9 in renal cell carcinoma, 植村 天受, K Shimizu, M Yoshikawa, M Tanaka, Y Hirao, K Yoshikawa, 18th Annual Meeting of European Association of Urology,   2003 , 18th Annual Meeting of European Association of Urology
  • Early phase ? trial with MN/CA9 antigen peptide vaccines restricted to HLA-A24 in renal cell carcinomas, 植村 天受, M Tanaka, M Cho, M Yoshikawa, Y Hirao, 94th Annual Meeting of American Association for Cancer Research,   2003 , 94th Annual Meeting of American Association for Cancer Research
  • Detection of circulating RCC cells in the renal vein during radical nephrectomy, 植村 天受, M Cho, Y Hirao, K Yoshikawa, 18th Urological Research Society Annual Meeting,   2001 , 18th Urological Research Society Annual Meeting
  • Cancer vaccines targeting MN/CA? antigen for renal cell carcinoma, 植村 天受, K Shimizu, M Cho, Eijiro Okajima, Y Hirao, S Saga, K Yoshikawa, 92th Annual Meeting of American Association for Cancer Research,   2001 , 92th Annual Meeting of American Association for Cancer Research
  • Vaccination of antigen peptide derived from MN/CA? induces specific immunity, 植村 天受, K Shimizu, M Cho, Y Hirao, K Yoshikawa, International Symposium Cancer Research Institute Tumor Vaccines 2000,   2000 , International Symposium Cancer Research Institute Tumor Vaccines 2000
  • Peptide vaccination of MN/CA? antigen induces specific tumor immunity, 植村 天受, K Shimizu, M Cho, M Yoshikawa, Y Hirao, K Yoshikawa, E Oosterwijk, 91th Annual Meeting of American Association for Cancer Research,   2000 , 91th Annual Meeting of American Association for Cancer Research
  • MN/CA? as a potential therapeutic target for active specific immunotherapy of renal cell carcinoma, 植村 天受, M Cho, H Shimizu, Y Nakagawa, K Yoshida, Y Hirao, K Yoshikawa, E Oosterwijk, 15th Congress of the European Association of Urology,   2000 , 15th Congress of the European Association of Urology
  • Active specific immunotherapy for RCC ?Vaccination of MN/CA? Ag peptide induces specific tumor immunity-, 植村 天受, K Shimizu, M Cho, M Yoshikawa, Y Hirao, K Yoshikawa, 17th Urological Research Society Annual Meeting,   2000 , 17th Urological Research Society Annual Meeting
  • G250 antigen as a potential target for immunotherapy of renal cell carcinomas, 植村 天受, Y Nakagawa, Y Hirao, K Yoshikawa, F Debruyne, E Oosterwijk, 14th Congress of the European Association of Urology,   1999 , 14th Congress of the European Association of Urology

Misc

  • Inductive Coupling Wireless Sensor-Transmitter for Continuous Monitoring of Intra-Bladder Pressure for Unconstrained Urodynamic Study, Proceedings of 5th International Workshop on Biosignal Interpretation, 193, 194,   2005 09
  • Effect of stimulated effect for urinary disorder in Parkinson’s disease using urodynamics., 46, 1, 68, 69,   2007 05